Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Hemispherx Biopharma (HEB), announced that as the Company works toward the re-launch of Alferon N, it has extended its agreement with Armada Health Care (Armada) for two years (through August 14 2017) for the sales/marketing of Alferon N Injection, its Food and Drug Administration approved natural interferon, in the US.
Subscribe to our email newsletter
Under this Agreement, the Company will manufacture and supply Alferon N Injection to physicians and patients through Armada’s national network of specialty pharmacies.
Armada has agreed to provide ongoing sales and marketing to support the product’s re-launch. Specialty Distributor, BioRidge Pharma (BRP), has received a two year contract extension and will warehouse, ship, and distribute Alferon N Injection on an exclusive basis for US sales.
"We have closely followed Hemispherx progress in its major upgrade of the Alferon manufacturing facility and we are pleased that this is now complete and we can continue to work on preparing for the re-launch of Alferon N Injection.
"As the only natural interferon approved in the U.S., we think Alferon N Injection has great potential in our market", stated Ryan Oligino, Executive Vice President Manufacturer Relations, Armada Health Care.
Wayne Springate, Senior Vice President of Operations for Hemispherx, stated "This extended agreement with Armada is gratifying. As leaders in the specialty pharmaceutical field, Armada is the ideal partner for the marketing and distribution of Alferon N Injection.
"Now with our upgrade work complete to include a high volume, state-of- the-art bioreactor for the manufacture of Alferon N Injection, we hope to be able to supply greater volumes of product to the market than in the past.
"We are also establishing an in-house team to support Armada and to establish other sales channels for Alferon N Injection, educate physicians and patients with the expectation to eventually drive sales in a growing and sustainable manner in the US, as well as in Europe, Latin America and Asia where we are actively seeking partners."